Evidence map›Paper›PMID 28815329›Full record

Trial reportJournal of gastroenterology2018

Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.

Yoshiiku Kawakami, Hidenori Ochi, Clair Nelson Hayes, Michio Imamura, Masataka Tsuge, Takashi Nakahara, Yoshio Katamura, Hiroshi Kohno, Hirotaka Kohno, Keiji Tsuji and 11 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 1 country.

Yoshiiku KawakamiDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Hidenori OchiDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Clair Nelson HayesDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Michio ImamuraDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Masataka TsugeDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Takashi NakaharaDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Yoshio KatamuraOnomichi General Hospital, Hiroshima, Japan.
Hiroshi KohnoKure Medical Center, Hiroshima, Japan.
Hirotaka KohnoKure Medical Center, Hiroshima, Japan.
Keiji TsujiHiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Shintaro TakakiHiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Nami MoriHiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Yohji HondaHiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Keiko AratakiTsuchiya General Hospital, Hiroshima, Japan.
Shoichi TakahashiKoyo New Town Hospital, Hiroshima, Japan.
Shinsuke KiraSaiseikai Hiroshima Hospital, Hiroshima, Japan.
Toru TamuraMazda Hospital, Hiroshima, Japan.
Kazunari MasudaMasuda Clinic, Hiroshima, Japan.
Toshio NakamuraNakamura Clinic, Hiroshima, Japan.
Masaya KikkawaKikkawa Clinic, Hiroshima, Japan.
Kazuaki ChayamaDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. chayama@mba.ocn.ne.jp.
Hiroshima University · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPKure Medical Center · JPHiroshima General Hospital · JPMazda Motor Corporation (Japan) · JPNakamura Toho Research Institute · JPOnomichi General Hospital · JPRIKEN · JPRIKEN Center for Integrative Medical Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Japan, daclatasvir (DCV) and asunaprevir (ASV) therapy was the first IFN-free treatment to be approved, and thousands of patients have since been successfully treated, with an SVR rate of around 90%. The converse, however, is that around 10% of patients fail to achieve viral eradication and must be retreated using a different approach. This study is to evaluate treatment efficacy of ledipasvir/sofosbuvir and ribavirin in patients who failed to respond to DCV and ASV therapy.

methodsThirty patients were treated with 12 weeks of ledipasvir/sofosbuvir and ribavirin. We evaluated the rate of sustained virological response 12 weeks after the end of treatment (SVR

resultsThe overall SVR

conclusionLedipasvir/sofosbuvir with ribavirin is an effective retreatment option for patients with chronic hepatitis C who failed to respond to prior daclatasvir and asunaprevir therapy.

Indexed as

AgedAged, 80 and overAntiviral AgentsBenzimidazolesCarbamatesDrug Therapy, CombinationFemaleFluorenesHepacivirusHepatitis C, ChronicHumansImidazolesIsoquinolinesMaleMiddle AgedPilot ProjectsAntiviral AgentsasunaprevirBenzimidazolesCarbamatesdaclatasvirFluorenesImidazolesIsoquinolinesledipasvir, sofosbuvir drug combinationPyrrolidinesRibavirinRNA, ViralSofosbuvirSulfonamidesUridine MonophosphateValineAsunaprevirDaclatasvirLedipasvir/sofosbuvir with ribavirinNS5A inhibitorNS5B polymerase inhibitorResistance-associated variantsRetreatment

Identifiers

PMID28815329
OpenAlexW2750211580

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.